Literature DB >> 16299530

To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control.

Ian Mohr1.   

Abstract

To ensure that their mRNAs are translated and that the viral proteins necessary for assembling the next generation of infectious progeny are produced, viruses must effectively seize control of the translational machinery within their host cells. In many cases, the ability to productively engage host translational components can determine if a given cell type can support viral replication, illustrating the critical importance of this task in the viral life cycle. Failure to interface properly with the host translational apparatus can compromise the productive growth cycle, resulting in an abortive infection and radically restricting viral replication. Not only have viruses become facile at commandeering this machinery, they are also particularly adept at manipulating cellular translation control pathways for their own ends. In this review, the mechanisms by which numerous viruses manipulate host translational control circuits are discussed. Furthermore, particular attention is devoted to understanding how interfering with the ability of a virus to properly regulate translation in its host can be exploited to generate oncolytic strains that selectively replicate in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16299530     DOI: 10.1038/sj.onc.1209053

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?

Authors:  Ryuichi Kanai; Hiroaki Wakimoto; Tooba Cheema; Samuel D Rabkin
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

2.  Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.

Authors:  Stephanie A Campbell; Matthew Mulvey; Ian Mohr; Matthias Gromeier
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 3.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 4.  Tinkering with translation: protein synthesis in virus-infected cells.

Authors:  Derek Walsh; Michael B Mathews; Ian Mohr
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-01-01       Impact factor: 10.005

5.  Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy.

Authors:  Feng Yao; Nao Murakami; Oliver Bleiziffer; Pengwei Zhang; Natali V Akhrameyeva; Ximing Xu; Richard Brans
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 6.  Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2013-04

Review 7.  Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.

Authors:  Ryuichi Kanai; Samuel D Rabkin
Journal:  CNS Oncol       Date:  2013-03

Review 8.  Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Authors:  Z Sheng Guo; Stephen H Thorne; David L Bartlett
Journal:  Biochim Biophys Acta       Date:  2008-02-15

9.  Effect of respiratory syncytial virus on the growth of hepatocellular carcinoma cell-lines.

Authors:  Song Hee Choi; Byoung Kwon Park; Keun-Wook Lee; Jun Chang; Younghee Lee; Hyung-Joo Kwon
Journal:  BMB Rep       Date:  2015-10       Impact factor: 4.778

10.  Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.

Authors:  Hannah M Burgess; Aldo Pourchet; Cristina H Hajdu; Luis Chiriboga; Alan B Frey; Ian Mohr
Journal:  Mol Ther Oncolytics       Date:  2018-01-31       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.